Diabetes increases the risk of cardiovascular (CV) and renal disease (CVRD). These become major causes of mortality in individuals with diabetes. In this touchENDOCRINOLOGY interview, Prof. Peter Rossing (University of Copenhagen, Copenhagen, Denmark) discusses the relationship between cardiovascular and renal risks in diabetes
The abstract entitled: ‘Effect of semaglutide on MACE by baseline kidney function in participants with type 2 diabetes and high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc analysis’ was presented at the European Association for the Study of Diabetes, 19-23 Sept, 2022.
- What is known about the relationship between cardiovascular and renal risks in diabetes? (0:18)
Disclosures: Peter Rossing is a consultant for Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, MSD, Novo Nordisk and Sanofi and discloses grant/research support from AstraZeneca and Novo Nordisk.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of EASD 2022
Share this Video
Related Videos In Diabetes
José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials
In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of the Rocket AP will be. The abstract entitled: ‘RocketAP in Practice: Results from Pilot and Feasibility […]
José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems
An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses the major challenges in the development of artificial pancreas systems. The abstract entitled: ‘RocketAP in Practice: Results from Pilot […]
Carol Levy, DTM 2022: The use of Control-IQ technology in prior MDI and basal-only insulin users with type 2 diabetes
In this touchENDOCRINOLOGY interview, Prof. Carol Levy (Icahn School of Medicine at Mount Sinai, New York City, NY, USA) discusses her study which evaluated adults with type 2 diabetes using the t:slim X2 insulin pump with Control-IQ technology to show that Control-IQ technology could offer considerable benefit to individuals with type 2 diabetes. The abstract […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!